Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says

Eton Pharmaceuticals (NASDAQ:ETON) had its price target increased by analysts at Craig Hallum from $23.00 to $26.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price target suggests a potential upside of 75.91% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. B. Riley reaffirmed a “buy” rating and set a $24.00 price objective (up previously from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price objective on shares of Eton Pharmaceuticals in a research report on Wednesday.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $14.78 on Wednesday. The stock has a market cap of $385.03 million, a price-to-earnings ratio of -67.18 and a beta of 1.37. The firm has a 50 day simple moving average of $15.56 and a 200-day simple moving average of $11.47. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. Equities analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $133,000. Two Sigma Advisers LP acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $662,000. Two Sigma Investments LP acquired a new stake in Eton Pharmaceuticals during the 4th quarter worth approximately $1,498,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Eton Pharmaceuticals by 18.3% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock valued at $141,000 after purchasing an additional 1,634 shares in the last quarter. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Eton Pharmaceuticals by 6.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock worth $3,688,000 after purchasing an additional 16,664 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.